Astec Lifesciences Limited (ASTEC) AI Stock Analysis

• Market Cap: ₹18.16B
• Dividend Yield: 0.16%
• Average Volume (3M): 2.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: 4.76%
• EPS Growth: -63.21%
• Country: IN
• Employees: 606
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): -9.70
• Shares Outstanding: 22,281,660
• 10 Day Avg. Volume: 885
• 30 Day Avg. Volume: 2,035
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹832.00
• Price Target Upside: 2.09% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: ₹832.00 ▲(2.09% Upside)

Astec Lifesciences Limited's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, negative margins, and liquidity issues. Technical analysis provides a slightly more positive outlook, with some indicators suggesting potential stability. However, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation score, further contributing to the low overall score.

Astec Lifesciences Limited Business Overview & Revenue Model

Company Description

Astec LifeSciences Limited, together with its subsidiaries, manufactures, distributes, and sells agrochemicals active ingredients and pharmaceutical intermediates in India. It manufactures a range of fungicides, insecticides, herbicides, and intermediates, such as triazole fungicides, heterocyclic herbicides, sulfonyl urea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, and silane derivatives; fluorinated aromatic amines, pyridine derivatives, aromatic carboxylic acids, benzyl alcohols, ketones and benzophenones, and heterocyclic mercaptans; fluorinated aromatic, aliphatic, and heterocyclic intermediates; heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, heterocyclic sulfonyl chlorides, heterocyclic sulphonamides, heterocyclic carbamates, thiourium salts, alkyl and aryl chloroformates, substituted pyrimidine diones, and pyrazolones; and substituted 1,2- and 1,3- pyrimidines. The company's products also comprise pyrazolyl aromatic ketones, morpholine derivatives, aromatic azo compounds, substituted triazines, imidate ethers, mesylated intermediates, substituted epoxides, ketals and bromo ketals, aromatic and aliphatic ethers, cyclopropyl ethers, cyclopropyl aldehydes and ketones, conjugated ketones, acetophenone derivatives, pinacolone derivatives, aliphatic and aromatic carboxylic acids, aliphatic and aromatic acid chlorides, halogenated and non-halogenated anhydrides, aliphatic alkenes, and halo alkanes; and aliphatic and aromatic brominated derivatives, cyanides, esters, carboxamides, amines, and alcohols and diols. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited.

How the Company Makes Money

Astec Lifesciences Limited makes money primarily through the manufacturing and sale of agrochemicals, which include active ingredients and intermediates used in the formulation of herbicides, fungicides, and insecticides. The company's revenue model is centered around supplying these chemicals to both domestic and international markets, serving agricultural companies and distributors. Key revenue streams for Astec include the direct sale of its chemical products, contract manufacturing services, and strategic partnerships or collaborations with other chemical and agricultural companies. These partnerships often enable the company to expand its distribution networks and enhance its market reach. Additionally, Astec's focus on research and development allows it to innovate and introduce new products, which can lead to increased sales and market share.

Astec Lifesciences Limited Financial Statement Overview

Summary

Astec Lifesciences Limited faces significant financial challenges. The income statement highlights declining revenue and profitability, with negative margins impacting overall performance. The balance sheet shows high leverage and decreasing equity ratios, increasing financial risk. Cash flow difficulties, marked by negative free cash flow, further exacerbate the situation, suggesting liquidity constraints and a need for strategic financial management.

Income Statement

The income statement shows a decline in revenue from 2023 to 2025, with a significant drop in gross profit and net income, resulting in negative margins. The company has experienced negative net profit margins in the most recent years, indicating profitability issues. The revenue growth has been negative, reflecting a challenging market environment or operational difficulties.

Balance Sheet

The balance sheet indicates high leverage with an increasing debt-to-equity ratio over the years, reflecting financial risk. The equity ratio has also decreased, signaling reduced asset backing by equity. Although the company maintains a positive stockholder's equity, the increasing liabilities pose a risk to financial stability.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow in recent years, highlighting liquidity issues. The operating cash flow to net income ratio is unfavorable, indicating a struggle to convert income into cash. Consistently negative free cash flow growth raises concerns about the company’s ability to sustain operations without external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.81B	3.81B	4.58B	6.28B	6.77B	5.55B
Gross Profit	324.69M	843.67M	1.33B	2.27B	2.86B	2.10B
EBITDA	-620.17M	-662.07M	-2.69M	893.14M	1.65B	1.19B
Net Income	-1.35B	-1.35B	-469.30M	255.65M	898.59M	650.49M
Balance Sheet
Total Assets	8.81B	8.81B	9.75B	9.79B	8.97B	6.78B
Cash, Cash Equivalents and Short-Term Investments	27.05M	27.05M	16.47M	27.54M	33.44M	15.42M
Total Debt	5.55B	5.55B	4.94B	3.41B	2.79B	1.87B
Total Liabilities	6.46B	6.46B	6.05B	5.60B	5.00B	3.68B
Stockholders Equity	2.35B	2.35B	3.69B	4.19B	3.96B	3.09B
Cash Flow
Free Cash Flow	0.00	-302.20M	-1.25B	-426.03M	-803.74M	-1.11B
Operating Cash Flow	0.00	-83.99M	102.21M	746.56M	236.04M	-81.62M
Investing Cash Flow	0.00	-152.30M	-1.35B	-1.13B	-1.04B	-731.10M
Financing Cash Flow	0.00	237.33M	1.25B	377.70M	804.77M	813.36M

Astec Lifesciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 815.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Negative. The current price of 815 is below the 20-day moving average (MA) of 843.53, below the 50-day MA of 853.51, and below the 200-day MA of 841.68, indicating a bearish trend. The MACD of -7.79 indicates Positive momentum. The RSI at 41.99 is Neutral, neither overbought nor oversold. The STOCH value of 13.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTEC.

Astec Lifesciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IOLCP	68 Neutral	₹30.49B	29.03	5.99%	0.77%	2.73%	-11.40%
IGPL	64 Neutral	₹12.94B	21.32	8.12%	2.38%	-1.78%	56.00%
PUNJABCHEM	64 Neutral	₹15.63B	33.89	10.67%	0.23%	9.24%	2.10%
HERANBA	48 Neutral	₹11.90B	387.71	0.37%	0.34%	―	―
ASTEC	45 Neutral	₹18.16B	―	―	0.16%	4.76%	-63.21%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%

Astec Lifesciences Limited Corporate Events

Astec LifeSciences Expands Equity Through Successful Rights Issue

Astec LifeSciences Limited announced the outcome of its Rights Issue Committee meeting held on July 29, 2025, where they approved the allotment of 26,69,951 equity shares on a rights basis to eligible shareholders at a price of ₹890 per share. This move increases the company’s paid-up equity share capital from 1,96,11,710 to 2,22,81,661 shares, potentially strengthening its financial position and market standing.

Astec LifeSciences Releases Q2 2025 Financial Results

Astec LifeSciences Limited has published its unaudited financial results for the quarter ending June 30, 2025, as approved by its Board of Directors. The results were announced through newspaper advertisements in Business Standard and Mumbai Lakshdeep, reflecting the company’s commitment to transparency and regulatory compliance.

Astec LifeSciences Limited Concludes 31st AGM with Key Resolutions

Astec LifeSciences Limited held its 31st Annual General Meeting (AGM) on July 28, 2025, via video conferencing, where key business matters were addressed. The meeting included the presentation of financial statements and audit reports, and shareholders were provided with electronic voting facilities. The results of the voting will be announced within two working days and made available on the company’s website, reflecting the company’s commitment to transparency and stakeholder engagement.

Astec LifeSciences Appoints New Secretarial Auditors for Five-Year Term

Astec LifeSciences Limited has announced the appointment of M/s. BNP & Associates as the secretarial auditors for a five-year term starting from the financial year 2025-26. This decision, approved at the company’s 31st Annual General Meeting, is expected to enhance the company’s compliance and governance standards, potentially strengthening its market position and stakeholder confidence.

Astec LifeSciences Reports Q2 2025 Financial Results

Astec LifeSciences Limited announced the approval of its unaudited financial results for the quarter ended June 30, 2025, during a board meeting held on July 28, 2025. The results, which were reviewed by the statutory auditors and received an unmodified opinion, reflect the company’s adherence to Indian Accounting Standards (IND AS) and demonstrate its commitment to transparency and regulatory compliance. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance for the specified period.